TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04675593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTAB-CV
Description: Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTAB-CV
Description: Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTAB-CV
Description: Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Monitoring
Description: The Self-Monitoring (control) group will monitor their medication adherence, take their blood pressure weekly with a home blood pressure monitor provided by the study after being trained by the study staff, and rate their mood weekly in response to a text reminder.
Study: NCT05093855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 Injection
Description: Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
Study: NCT06028919

Intervention type: DEVICE
Group type: OTHER
Intervention: Temperature controlled DiamondTemp (DT) ablation catheter
Description: The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.

Intervention type: DEVICE
Group type: OTHER
Intervention: Tacticath/Tactiflex (TF) ablation catheter
Description: The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.
Study: NCT04579991

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel
Description: Topical product, apply small amount on mucosal surface of vulva included clitoris once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Emulgel-only
Description: Topical placebo product, apply small amount on mucosal surface of vulva included clitoris once daily
Study: NCT05732298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittend theta burst stimulation (iTBS)
Description: 600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday
Study: NCT04682197

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset Research
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study: NCT04639271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Plus And
Description: Pyrotinib::400mg/d,qd,po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 125mg/M2, qw iv
Study: NCT04682197

Intervention type: DEVICE
Group type: OTHER
Intervention: Cereset Research
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study: NCT05058976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Monthly dose: 210 mg subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly saline injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: 5 mg IV infusion at Month 12 Visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 5 mg IV infusion at Month 12 Visit

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
Study: NCT04960046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an infraclavicular perineural catheter using a costoclavicular approach
Description: The high-frequency linear probe will be used to image the axillary artery in the long axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, also in its distal third. The needle will be inserted with a latero-medial orientation in the plane. The initial injection will be a single injection laterally to the axillary artery, where the three nerve bundles are still joined together.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placement of an infraclavicular perineural catheter by paracoracoid approach
Description: The high-frequency linear probe will be used to image the axillary artery in the short axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, in its distal third. The needle will be inserted with a cranio-caudal orientation in the plane. The initial injection will be a single injection posterior to the axillary artery, the expected distribution being a U distribution around the artery.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing.
Study: NCT05963880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)
Description: All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)
Description: All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)
Description: All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)
Description: All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
Study: NCT05584059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Acceptance and Commitment Therapy
Description: This is an individual-based FACT counselling programme which composes of 4-6 sessions on a weekly basis (45-60mins/session). All the sessions are delivered by a trained FACT interventionist via either video-conferencing (e.g., Zoom or Windows Teams) or face-to-face format. The programme aims to increase the psychological flexibility of the parent, so that he/she is able to (i) experience the present moment and take perspective on self (i.e., Awareness); (ii) detach the distressing private experiences and associated rules and to take a non-judgemental, accepting stance toward the painful experiences (i.e., Openness) and (iii) exhibits strong connection with values and commit to values-consistent actions. The trained interventionist will use different ACT strategies in these sessions, including ACT metaphors, experiential exercises, guided mindfulness exercises, guided imagery exercises and values clarification exercises to reinforce the above principles.
Study: NCT05272683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: On day 1 and day 8, participants will receive a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: On days 5 to 11, participants will receive itraconazole once daily
Study: NCT05011188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FOR46
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FOR46
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given orally (PO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given subcutaneously (subQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given subcutaneously (subQ)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Samples
Description: Blood samples will be taken for correlative studies
Study: NCT06384066

Intervention type: OTHER
Group type: OTHER
Intervention: GetWell Mobile Application
Description: GetWell utilizes an interactive health care application to allow patients to participate in their care. We plan to work with GetWell to develop a custom built plan for urethroplasty patients and provide patient education.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Office Based Pathway

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Office Based Pathway
Study: NCT04975841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Derived Regenerative Cells
Description: The Cytori Celution technology is an automated version of the process and techniques used in the research laboratory to isolate regenerative cells from adipose tissue. The Cytori Celution System uses a proteolytic enzyme blend (Celase) to disrupt the adipose tissue matrix and release the entrapped adipose derived regenerative cells (ADRCs), also referred to in the literature as stromal vascular fraction cells. Once digested, the digestate is separated into fractions (buoyant adipocytes (fat cells) and pelleted ADRCs) by centrifugation. The non-buoyant cell pellet (ADRCs) is then washed and centrifuged through several cycles to remove residual enzyme reagent and cellular debris. Although the Cytori Celution technology replicates known laboratory techniques, it offers significant improvements to the manual laboratory technique by controlling the processing in a closed system that has been validated for safety, performance, and reproducibility.
Study: NCT06511973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen (BAYH006689)
Description: BAYH006689 gel will be dispensed directly on the patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo gel will be dispensed directly on the patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A solution of 0.9% Saline
Description: 0.9% Saline will be dispensed directly on the patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A solution of 0.2% SLS
Description: 0.2% SLS will be dispensed directly on the patch.
Study: NCT06065488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ankle kinesio tap
Description: Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ankle kinesio tap
Description: Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.
Study: NCT05163041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT7480
Description: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT7480
Description: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT7480
Description: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT7480
Description: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT7480
Description: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
Study: NCT05968274

Intervention type: DEVICE
Group type: OTHER
Intervention: Rebox-Physio 4 (real stimulation)
Description: Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.

Intervention type: DEVICE
Group type: OTHER
Intervention: Rebox-Physio 4 (real stimulation)
Description: Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.

Intervention type: DEVICE
Group type: OTHER
Intervention: Rebox-Physio 4 (sham stimulation)
Description: In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded.

Intervention type: DEVICE
Group type: OTHER
Intervention: Rebox-Physio 4 (sham stimulation)
Description: In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded.
Study: NCT06550375

Intervention type: DEVICE
Intervention: TECNIS Odyssey IOL
Description: Implantation with the TECNIS Odyssey IOL
Study: NCT05828862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypotension prediction index guidance
Description: using hypotension prediction index guidance to prevent intraoperative hypotension
Study: NCT05972278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: 1 tablet daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obicetrapib
Description: 1 tablet daily
Study: NCT05196828

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTX100 Neuromodulation System
Description: Active Noninvasive peripheral nerve stimulation device programmed to active mode
Study: NCT04595773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercise Training
Description: Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.
Study: NCT05478421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen sponge
Description: The bone cavity will be filled with collagen sponge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GBR
Description: The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CS/GBR
Description: The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
Study: NCT05400317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-218
Description: PO, Once daily(QD), 12weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-218A
Description: PO, Once daily(QD), 12weeks
Study: NCT06034210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised 3D-printed insoles
Description: Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
Study: NCT06045988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Contact Sleep Quality Monitor System
Description: Residents of long-term care facilities with Alzheimer's or other related dementias will utilize a sleep monitoring device for the four-week period they are involved in the study.